1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Mylan Sees COVID-19 Impact On Sales

Also Exploring International Listings For Viatris After Upjohn Merger

 
• By Dave Wallace

Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.

Roller coaster
A rise in Q1 has been followed by a corresponding drop in Q2 • Source: Shutterstock

Mylan has seen its sales slump in Europe and in the rest of the world in the second quarter of 2020 due to COVID-19, balancing out the additional demand that had been seen by the company in the first quarter. (Also see "Mylan Delays Restructuring Amid COVID-19" - Generics Bulletin, 14 May, 2020.)

In North America, higher volumes of products such as Mylan’s Wixela Inhub (fluticasone/salmeterol) rival to Advair Diskus and sales from newly launched products helped to offset pricing pressures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.